Leading neurologists and researchers to provide strategic and clinical guidance as Slate Medicines progresses SLTE-1009 and a broader pipeline of migraine therapeutics.

RALEIGH, N.C. — Slate Medicines, a privately-held biotech company advancing next-generation therapeutics for migraine and other headache disorders, today announced the formation of a Scientific Advisory Board (SAB) and a Clinical Advisory Board (CAB). The two boards bring together internationally recognized neurologists and researchers who will provide strategic and clinical guidance as the Company advances its lead program, SLTE-1009, an anti-PACAP/VIP monoclonal antibody, along with its broader pipeline.

“The formation of our Scientific and Clinical Advisory Boards marks an important milestone for Slate,” said Gregory Oakes, Chief Executive Officer of Slate Medicines. “As we advance SLTE-1009 and build out our pipeline, the insight and guidance of leaders who have spent their careers advancing the field of headache medicine will be invaluable in shaping our overall company strategy. Their guidance will help ensure that every decision we make, from clinical trial design to long-term portfolio advancement, is grounded in the realities of patient care.”

Members of the Scientific and Clinical Advisory Boards include:

Scientific Advisory Board

• Andrew Blumenfeld, M.D. – Faculty Neurologist, Cedars-Sinai; Director, Haven Headache & Migraine Center
• Peter Goadsby, M.D., Ph.D., FRS – Dean of Biomedical Sciences, King Abdullah University of Science and Technology, Saudi Arabia; Latterly, Professor of Neurology and Neurologist, King’s College London; Emeritus Professor of Neurology, UCLA
• Richard B. Lipton, M.D. – Professor of Neurology and Director of the Montefiore Headache Center; Director, Division of Cognitive Aging and Dementia, Albert Einstein College of Medicine

Clinical Advisory Board

• Jessica Ailani, M.D., FAHS, FAAN – Neurologist and Headache Specialist, Washington, DC
• Christopher Gottschalk, M.D., FAHS – Professor of Clinical Neurology and Director, Headache & Facial Pain Program, Yale Medicine
• Stewart J. Tepper, M.D., FAHS – Vice President, New England Institute for Neurology and Headache

“This is truly a remarkable group of clinicians and investigators,” said Roger Cady, M.D., Chief Medical Officer of Slate Medicines. “Collectively, our advisors represent decades of leadership in migraine and headache research, drug development, and patient care, including foundational work on CGRP and other migraine-relevant biology. Their combined expertise gives us an exceptional vantage point as we work to bring a differentiated, orthogonal approach to migraine prevention to patients who remain underserved by existing therapies.”

About Slate Medicines, Inc.

Slate Medicines is a biotech company focused on advancing next-generation therapeutics for migraine and other headache disorders. The Company’s lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP/VIP for the prevention of migraine. The company is backed by leading healthcare investors including RA Capital Management, Forbion, Foresite Capital, and an additional undisclosed biotech investor. For more information, please visit www.slatemedicines.com.

Media and Investor Contacts
ICR Healthcare
slate@icrhealthcare.com

RALEIGH, N.C. — Slate Medicines, a privately-held biotech company advancing next-generation therapeutics for migraine and other headache disorders, announced the appointment of John Umstead, CPA, as Chief Financial Officer, effective May 2026. Mr. Umstead brings extensive financial leadership experience across all stages of biopharmaceutical company development, from clinical through commercial operations.

“We are thrilled to welcome John to the Slate Medicines team,” said Gregory Oakes, MBA, Chief Executive Officer of Slate Medicines. “His proven track record in financial strategy and capital markets will be invaluable as we advance SLTE-1009 into Phase 1 clinical trials and work to expand the treatment paradigm for the millions of migraine patients who remain underserved by current therapies.”

Mr. Umstead brings comprehensive expertise in accounting, financial operations, financial planning and analysis, treasury management, and capital markets. Most recently, he served as Chief Financial Officer of G1 Therapeutics, Inc., a publicly traded commercial-stage oncology company that was acquired by Danish drugmaker Pharmacosmos. Prior to G1 Therapeutics, Mr. Umstead worked at PricewaterhouseCoopers LLP (PwC), where he served clients ranging from small private companies to large publicly traded corporations. He began his career at PwC in the audit and assurance practice before advancing to the Capital Markets Accounting and Advisory Services group, where he advised companies on complex accounting and financial reporting matters related to business combinations, debt and equity financings, divestitures, IPO readiness, and technical accounting issues. Before joining PwC, Mr. Umstead spent five years in commercial banking.

“I am excited to join Slate Medicines at this pivotal moment,” said Mr. Umstead. “The company’s focus on addressing the significant unmet needs of migraine patients through PACAP-targeting therapeutics represents a compelling opportunity to expand the treatment paradigm. With the company’s strong financial foundation from its $130 million Series A financing and upcoming Phase 1 clinical trials for SLTE-1009, I look forward to working with the team to advance therapies for the millions of patients who continue to experience substantial disease burden despite current treatment options.”

Mr. Umstead earned a Master of Accounting and a Bachelor of Arts from The University of North Carolina at Chapel Hill and is a certified public accountant.

About Slate Medicines, Inc.
Slate Medicines is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. The Company’s lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP/VIP for the prevention of migraine. The company is backed by leading healthcare investors including RA Capital Management, Forbion, Foresite Capital, and an additional undisclosed biotech investor. For more information, please visit www.slatemedicines.com.

Media and Investor Contacts
Simona Kormanikova
ICR Healthcare
slate@icrhealthcare.com